| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1039882527 |
| P356 | DOI | 10.2165/11596950-000000000-00000 |
| P698 | PubMed publication ID | 22540371 |
| P2093 | author name string | Sandra de Bie | |
| Bruno H Ch Stricker | |||
| Myrthe P P van Herk-Sukel | |||
| Peter G M Mol | |||
| Loes E Visser | |||
| Sabine M J M Straus | |||
| Ron M C Herings | |||
| Silvana A Romio | |||
| Rikje Ruiter | |||
| Petronella H Geelhoed-Duijvestijn | |||
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Changes in glitazone use among office-based physicians in the U.S., 2003-2009. | Q33751542 | ||
| Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone | Q34123137 | ||
| Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality | Q34127761 | ||
| Rosiglitazone: a European regulatory perspective. | Q34154718 | ||
| Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis | Q34634794 | ||
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
| Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone | Q37572625 | ||
| Clinical consequences of disseminating the rosiglitazone FDA safety warning. | Q37747333 | ||
| A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. | Q39871580 | ||
| Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure | Q43519749 | ||
| Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006). | Q44335629 | ||
| Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. | Q45924271 | ||
| Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus | Q46699265 | ||
| Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). | Q47625602 | ||
| Co-dispensing of contraindicated medications in patients using cisapride in Italy. | Q51805289 | ||
| Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. | Q51900061 | ||
| Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert | Q83723528 | ||
| [Diabetes mellitus in the Netherlands: estimate of the current disease burden and prognosis for 2025] | Q84565123 | ||
| P433 | issue | 6 | |
| P921 | main subject | Netherlands | Q55 |
| (RS)-rosiglitazone | Q424771 | ||
| P304 | page(s) | 471-480 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008. | |
| P478 | volume | 35 |
| Q85365363 | Author's reply to Carracedo-Martínez E comment on: "prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in The Netherlands from 1998 to 2008" |
| Q36964223 | Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure |
| Q45195719 | Comment on: prescribing of rosiglitazone and pioglitazone following safety signals analysis of trends in dispensing patterns in The Netherlands from 1998 to 2008. |
| Q28534696 | Differential impact of two risk communications on antipsychotic prescribing to people with dementia in Scotland: segmented regression time series analysis 2001-2011 |
| Q53539049 | Effects of a primary care intervention to improve the quality of zolpidem prescriptions in elderly patients. |
| Q40649706 | Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. |
| Q38502148 | Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy |
| Q38644070 | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies. |
| Q39711572 | Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal. |
| Q37185836 | Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study |
| Q47653552 | Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations |
| Q42695721 | Media attention regarding sudden cardiac death associated with domperidone use does not affect in hospital ECG recording |
| Q36541917 | Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women |
| Q57037781 | Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron |
| Q36620262 | Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone |
| Q37591802 | Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel - proton pump inhibitor interaction. |
| Q34623567 | Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010. |
| Q86748291 | The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis |
| Q39422837 | The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist |
| Q38836416 | Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit |
| Q35141084 | Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings. |
Search more.